EHA 2018 | Improving outcomes for R/R DLBCL with polatuzumab vedotin

Marek Trněný and Marek Trneny

Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses a recent trial (NCT02257567) that aimed to improve care for these patients using a combination therapy of bendamustine, rituximab and the antibody-drug conjugate polatuzumab vedotin. The positive survival data from this study suggest a new treatment avenue for patients who previously had few options.

Share this video